Evidence map›Paper›PMID 41501178›Full record

ArticleNature cell biology2026

p53 increases phospholipid headgroup scavenging in senescence.

Jossie J Yashinskie, Xianbing Zhu, Grace H McGregor, Karl A Wessendorf-Rodriguez, Katrina Paras, Julia S Brunner, Benjamin T Jackson, Abigail Xie, Richard Koche, Christian M Metallo and 1 more

Abstract read
In one paragraph

Article in Nature cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jossie J Yashinskie *Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Xianbing Zhu *Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Grace H McGregorDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Karl A Wessendorf-RodriguezDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Katrina ParasCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9743-5710
Julia S BrunnerCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin T JacksonCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-1089-4362
Abigail XieCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-6820-5083
Christian M MetalloDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-2404-3040
Lydia W S FinleyCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. finleyl@mskcc.org.ORCID http://orcid.org/0000-0003-4023-7574

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Weill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6M
Training Program in Developmental BiologyT32HD060600 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI BAO, ZHIRONG, STUHLMANN, HEIDI · 2010 to 2024
$3.5M
Regulation of tumor suppression by alpha-ketoglutarateR37CA252305 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FINLEY, LYDIA · 2020 to 2025
$3.4M
Non-essential amino acids and sphingolipid diversity in cancer progressionR01CA234245 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI METALLO, CHRISTIAN MICHAEL · 2019 to 2023
$1.9M
Metabolic vulnerabilities in cancers with impaired TCA cycle activityF30CA284711 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Abigail Xie · 2023 to 2026
$216k
Metabolic control of exit from naïve pluripotencyF30HD107943 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI JACKSON, BENJAMIN TONNU · 2022 to 2025
$184k
NCI NIH HHS F30 CA284711NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA234245NCI NIH HHS R37 CA252305NICHD NIH HHS F30 HD107943NICHD NIH HHS T32 HD060600NIGMS NIH HHS T32 GM007739NIGMS NIH HHS T32 GM152349U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) F30HD107943U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) T32HD060600U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F30CA284711U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA008748U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA234245U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA252305U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007739
6 · The paper itself

Abstract

Changes in cell state are often accompanied by altered metabolic demands, and homeostasis depends on cells adapting to their changing needs. One major cell state change is senescence, which is associated with dramatic changes in cell metabolism, including increases in lipid metabolism, but how cells accommodate such alterations is poorly understood. Here we show that the transcription factor p53 increases recycling of the lipid headgroups required to meet the increased demand for membrane phospholipids during senescence. p53 activation increases the supply of phosphoethanolamine, an intermediate in the Kennedy pathway for de novo synthesis of phosphatidylethanolamine, in part by increasing lipid turnover and transactivating genes involved in autophagy and lysosomal catabolism that enable membrane turnover. Disruption of phosphoethanolamine conversion to phosphatidylethanolamine is well tolerated in the absence of p53 but results in dramatic organelle remodelling and perturbs growth and gene expression following p53 activation. Consistently, CRISPR-Cas9-based genetic screens reveal that p53-activated cells preferentially depend on genes involved in lipid metabolism and lysosomal function. Together, these results reveal lipid headgroup recycling to be a homeostatic function of p53 that confers a cell-state-specific metabolic vulnerability.

Indexed as

Cellular SenescencePhosphatidylethanolaminesPhospholipidsTumor Suppressor Protein p53AnimalsAutophagyHumansLipid MetabolismLysosomesphosphatidylethanolaminePhosphatidylethanolaminesPhospholipidsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID41501178
PMCPMC12904796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.